Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 10 and January 13, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold shares of the company's common stock.
• The sales occurred on January 10, 2025, and January 13, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On January 10, 2025, 56 shares were sold at a weighted average price of $10.02, with prices ranging from $10.00 to $10.38.
• On January 13, 2025, 56 shares were sold at a weighted average price of $10.1, with prices ranging from $10.00 to $10.20.
• Following these transactions, Mr. Ma directly owns 1,057 shares and indirectly owns 2,915,138 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is neutral as it reports routine stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Insider trading activity is common and closely monitored. Rule 10b5-1 plans allow insiders to sell shares at predetermined times to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation practices, including stock sales, are common across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also have executives who utilize 10b5-1 trading plans.
• The volume of shares sold is relatively small compared to the total shares owned by Mr. Ma.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, although the use of a 10b5-1 plan mitigates this concern.

Key Dates